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in this process, by pathway analysis. A total of 3430 pro-
teins were identified with a false detection rate of <1 %, of 
which 1117 were quantified at every time point. Increasing 
numbers of significantly differentially expressed proteins 
compared with the freshly isolated cells were observed 
at 24 h (40 proteins), 72 h (118 proteins) and 168 h (272 
proteins) (p < 0.05). In particular, cytochromes P450 and 
mitochondrial proteins underwent major changes, con-
firmed by functional studies and investigated by pathway 
analysis. We report the key factors and pathways which 
underlie the loss of hepatic phenotype in vitro, particularly 
those driving the large-scale and selective remodelling of 
the mitochondrial and metabolic proteomes. In summary, 
these findings expand the current understanding of dedif-
ferentiation should facilitate further development of simple 
and complex hepatic culture systems.
Keywords Cytochrome P450s · Human hepatocytes · 
Mass spectrometry · Mitochondria · iTRAQ · Donor-
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Abbreviations
PHH  Primary human hepatocytes
DILI  Drug-induced liver injury
CYP  Cytochrome P450
LETFs  Liver-enriched transcription factors
HNF  Hepatic nuclear factor
HLC  Hepatocyte-like cell
MAPKs  Mitogen-activated protein kinases
NFκB  Nuclear factor kappa-light-chain-enhancer of 
activated B cells
DEPs  Differentially expressed proteins
ROS  Reactive oxygen species
HSF  Heat shock factor protein
ERK  Extracellular signal-regulated kinase
Abstract The application of primary human hepatocytes 
following isolation from human tissue is well accepted to 
be compromised by the process of dedifferentiation. This 
phenomenon reduces many unique hepatocyte functions, 
limiting their use in drug disposition and toxicity assess-
ment. The aetiology of dedifferentiation has not been well 
defined, and further understanding of the process would 
allow the development of novel strategies for sustaining the 
hepatocyte phenotype in culture or for improving protocols 
for maturation of hepatocytes generated from stem cells. 
We have therefore carried out the first proteomic compari-
son of primary human hepatocyte differentiation. Cells 
were cultured for 0, 24, 72 and 168 h as a monolayer in 
order to permit unrestricted hepatocyte dedifferentiation, so 
as to reveal the causative signalling pathways and factors 
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BSEP  Bile salt export pump
MDR  Multiple drug resistance protein
MRP  Multidrug resistance-related protein
SLC  Solute carrier family of transporters
Introduction
Primary human hepatocytes (PHHs) are an important tool 
for studying human liver disease and drug-induced liver 
injury (DILI), with other models, such as rat hepatocytes, 
hepatic cell lines and stem cell-derived hepatocyte-like 
cells failing to offer metabolically competent and species-
relevant alternatives (Godoy et al. 2013). However, access-
ing and culturing PHHs remains difficult due to inconsist-
ent supply and an inability to stimulate sufficient division 
for in vitro expansion. Furthermore, following isolation, 
primary human hepatocytes undergo a rapid dedifferentia-
tion process in which many unique hepatocyte characteris-
tics are lost, reducing the physiological relevance of the 
model (Fraczek et al. 2013; Godoy et al. 2013).
It is thought that dedifferentiation is caused by inflamma-
tory and proliferative-associated responses to both PHH isola-
tion and subsequent in vitro culture (Elaut et al. 2006; Fraczek 
et al. 2013; Godoy et al. 2009; Zellmer et al. 2010). Current 
models of dedifferentiation hypothesise that these responses 
result in the down-regulation of important liver-enriched 
transcription factors (LETFs) such as hepatic nuclear fac-
tors (HNFs), HNF1α and HNF4α, which control many of the 
ADME processes (absorption, distribution, metabolism and 
excretion) and other features unique to PHHs, resulting in a 
loss of hepatic phenotype (Godoy et al. 2009; Zellmer et al. 
2010); however, the exact mechanisms which govern these 
changes remain incompletely understood.
Several approaches have been adopted to maintain the 
hepatocyte phenotype in culture, including co-culture and 
3D models such as sandwich cultures, bioreactors, liver buds 
and spheroids which attempt to better replicate the in vivo 
hepatic environment (Darnell et al. 2012; No et al. 2012; 
Tostoes et al. 2012). In addition, a wide range of growth 
factors, cytokines and small molecules have also been used 
to target and maintain the hepatic phenotype, such as those 
shown recently by Shan et al. (Shan et al. 2013). Many of 
these strategies have been thoroughly reviewed by both 
Godoy et al. (2013) and Fraczek et al. (2013).
Despite these continued improvements and advances 
towards complex culture conditions which can maintain 
an improved phenotype over a period of weeks, the full 
in vivo phenotype has not yet been achieved. Therefore, 
there remains a real need to improve the understanding of 
the underlying causes of this process and to identify novel 
strategies/targets for intervention. Moreover, as complex 
models reduce the effects of dedifferentiation, analysis of 
these systems may result in the underlying causes being 
difficult to fully ascertain. Therefore, studies of more rudi-
mentary models which result in more pronounced dediffer-
entiation may consequently provide a greater insight into 
the partially understood and currently unknown causes of 
dedifferentiation.
Crucially, increased understanding of dedifferentiation 
is also likely to be useful in guiding attempts to direct and 
maintain a hepatic phenotype from pluripotent cells in vitro. 
Current efforts worldwide have not taken a cell beyond a 
relatively immature hepatocyte (Kia et al. 2013), and it can 
be hypothesised that an integral part of this challenge is how 
we can capture the hepatic phenotype and prevent its loss.
Global studies offer an insight into how cells react in a 
holistic sense to a particular condition, and whilst efforts 
have been made to map changes in the hepatocyte tran-
scriptome during dedifferentiation (Kim et al. 2010; Lasher 
et al. 2011), many changes key to the mature phenotype of 
the hepatocyte are not properly represented in such analy-
sis. This is exemplified by the recent results, showing that 
only ~40 % of the variation in cell protein levels can be 
explained by differences in the corresponding mRNA lev-
els (Schwanhausser et al. 2011). We have previously shown 
that the use of a global proteomic approach to phenotype 
rat hepatocytes can provide novel information on dediffer-
entiation (Rowe et al. 2010) and here look to build on that 
study using human cells.
We have therefore now followed PHHs over the first 
7 days of monolayer culture, chosen specifically to exac-
erbate the effects of dedifferentiation. Using iTRAQ-based 
stable isotope labelling and pathway analysis, we have 
identified the key changes in the PHH proteome during 
dedifferentiation and the inter-donor variability, which 
exists not only in donor phenotype, but also in the subse-
quent dedifferentiation profile.
Materials and methods
Primary human hepatocyte isolation
Primary human hepatocytes were isolated using a previ-
ously described 2-step collagenase method (LeCluyse et al. 
2005). Briefly, liver resections were received as surgical 
waste (Aintree hospital, Liverpool, UK) with full patient 
consent and ethical approval. The resections were perfused 
with HEPES-buffered saline (HBS; 10 mM Hepes, 5 mM 
KCl, 136 mM NaCl, 5 g/l glucose), followed by digestion 
with Collagenase A or IV (Roche, Basel, Switzerland or 
Sigma-Aldrich, St. Louis, MO) in HBS containing 700 µM 
CaCl2. The capsule was then opened and the digested cells 
separated using gauze. The suspension was centrifuged twice 
at 80xg for 5 min at 4 °C and resuspended in Williams E 
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medium (Sigma-Aldrich, St. Louis, MO). Cells were plated 
onto collagen-I-coated plates (BD Dickinson, San Jose, CA) 
at 2.5 × 105 cells/cm2 to achieve full confluency, in Williams 
E supplemented with 1 % insulin–transferrin–selenium (Life 
Technologies, Carlsbad, CA), 2 mM l-glutamine (Sigma-
Aldrich, St. Louis, MO), 10−7 M dexamethasone and peni-
cillin (100 units/ml)/streptomycin (100 µg/ml) (Sigma-
Aldrich, St. Louis, MO). After 3 h, non-attached cells were 
washed away and the culture medium was replaced.
iTRAQ
Fresh samples were collected directly after isolation, before 
cells were plated. Samples were spun at 80×g for 5 min 
and lysed in 100 µl iTRAQ buffer. In total, 24, 72 and 
168 h time points were collected directly from 6 wells of 
a 24-well plates in a total of 100 µl iTRAQ buffer. Protein 
concentration was determined by Bradford assay. Protein 
lysates derived from five donors were labelled according 
to the manufacturer’s instructions (Applied Biosystems, 
Foster City, CA). One hundred micrograms protein in 20 µl 
of iTRAQ buffer was denatured, and the protein cysteine 
residues were reduced with tris(2-carboxyethyl)phosphine 
for 1 h at 60 °C and subsequently capped with methylmeth-
anethiosulfate, before overnight digestion with reconsti-
tuted trypsin at 37 °C. Isopropanol was then added to each 
sample, before labelling with differentially weighted iso-
baric tags for 2 h, at room temperature. The labelled sam-
ples were then pooled and made up to 5 mL with 10 mM 
potassium dihydrogen phosphate/25 % w/v acetonitrile. 
The pH was then adjusted using concentrated phosphoric 
acid to <pH 3, before cation-exchange chromatography, 
followed by identification with mass spectrometry, as 
described previously (Rowe et al. 2010, 2013). Samples 
were run across three 8-plex iTRAQ runs (table S1), and 
results obtained relative to each donor’s fresh sample to 
control for inter-donor variation.
Proteomic data analysis
Following iTRAQ analysis, only proteins, which were pre-
sent in all samples, identified with 95 % confidence (2 or 
more peptides) or 99 % confidence (single peptide) with a 
false detection rate (FDR) of less than 1 % were statisti-
cally analysed using R open-source software (http://www.r-
project.org/). The iTRAQ output was analysed and differen-
tially expressed proteins (DEPs) identified using the linear 
models for microarray data (LIMMA) and t test (multtest) 
modules as described previously (Ritchie et al. 2015; Rowe 
et al. 2010). The R script and raw iTRAQ outputs used to 
generate the data are provided as supplementary informa-
tion. Statistical outputs (p value, Benjamini–Hochberg 
and log fold change) of these modules were presented as 
volcano plots, and proteins detected in all samples were 
subjected to hierarchical clustering and heatmap analysis.
Further proteomic data analysis
Individual trend analysis of CYPs and transporters detected 
in ≥3 donors was assessed by one-way ANOVA. Coeffi-
cient of variance (CV) was calculated as (standard devia-
tion/mean). The most variable proteins were defined as 
CV > 1.3, and the most stable proteins were defined as 
CV < 0.3 and a mean relative fold change >0.8 and <1.25. 
PANTHER analysis was used to categorise differential sub-
sets of proteins into biological functional groups and dis-
played as a pie chart (Mi et al. 2013).
Pathway analysis
Significant DEPs (p < 0.05) were uploaded to the Ingenu-
ity platform IPA (Qiagen, Venlo, Netherlands) to investi-
gate the associated pathways, networks and regulators. IPA 
uses a database of known protein interactions from scien-
tific publications to associate and group the uploaded DEPs 
with pathways (Thomas and Bonchev 2010). Using IPA 
algorithms, the software generates a p value which relates 
to the likelihood that a particular pathway or network is 
linked to the DEPs in the dataset. Only pathways that were 
altered by p < 0.05 (Fisher exact t test) were classed as sig-
nificantly altered or linked. The Z-activation score, which 
additionally takes into account the directional change of 
the proteins, was used for biological function and upstream 
regulator analysis. Using the IPA algorithm, functions or 
regulators that have a Z-score of ≥2 are predicted to be 
activated and ≤−2 are predicted to be inhibited.
Transcription factor binding analysis
Mapper2 online software was used to compare the predicted 
transcription factor binding sites (Marinescu et al. 2005). 
Analysis was completed using the collated database, ana-
lysing the sequence of each gene 2000 base pairs upstream 
of the transcription start site. The number of proteins of 
interest which interacted with each predicted transcription 
factor was then compared to determine the significance of 
each factor. Those factors which demonstrated enriched 
predicted binding within a subset of proteins (≥4 proteins) 
were classed of factors of interest.
Western blotting
Samples collected in iTRAQ buffer were quantified by 
Bradford assay and assessed by western blot to validate 
iTRAQ results. Briefly, 5 µg samples were denatured at 
80 °C in Laemmli sample buffer (Sigma-Aldrich, St. Louis, 
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MO) and separated in 10 % polyacrylamide gels and then 
transferred to nitrocellulose membranes (G.E Healthcare, 
Buckinghamshire, UK). Following 1 h blocking in 10 % 
milk (Bio-Rad, Hercules, CA), primary antibodies directed 
against CYP2E1 (Abcam, Cambridge, UK; 1:5000), 
CYP2D6 (BD Gentest, San Jose, CA; 1:1000), CYP1A2 
(Abcam, Cambridge, UK; 1:3000) were added overnight 
or for 15 min Actin (Abcam, Cambridge, UK; 1:10,000). 
Following washing, secondary mouse (1:10,000; CYP2D6, 
CYP1A2, Actin) or rabbit (1:5000; CYP2E1) antibodies 
were subsequently added for 1 h. Membranes were then 
washed and visualised using chemiluminescence.
Metabolism studies
To determine the metabolic changes that occur in PHH dur-
ing dedifferentiation, we used quantitative mass-spectrome-
try-based activity assays. PHHs were incubated for 15 min 
at 37 °C (5 % CO2) at a final substrate cocktail concentration 
of 1 mM testosterone (CYP3A4) and 0.25 mM dextrometho-
rphan (CYP2D6) (both purchased from Sigma-Aldrich, St. 
Louis, MO) in MeOH or H2O, respectively (Fisher Scien-
tific, Pittsburgh, PA), in culture media. 0.5 mM Phenacetin 
(Sigma-Aldrich, St. Louis, MO) in 100 % MeOH was then 
added to the incubation media (1:1 v/v) as a stop solution and 
an internal standard for LC–MS–MS analysis. The media 
containing the respective metabolites, 6β-OH-testosterone 
and dextrorphan, were then quantified by LC–MS-MS. This 
was repeated for the 24, 48, 72 and 168 h time points.
Seahorse functional mitochondrial assay
PHH isolated from subsequent donors were cultured on 
collagen-I-coated (Life Technologies, Carlsbad, CA; 
50 µg/ml in 0.02 M acetic acid), XF 96-well cell culture 
microplates (Seahorse biosciences, North Billerica, MA; 
2.5 × 104 cells/well). OXPHOS stress test medium was 
supplemented with 25 mM d-glucose, 2 mM l-glutamine 
and 1 mM sodium pyruvate (final concentration). The 
glycolytic stress test medium was prepared by adding 
2 mM l-glutamine (final concentration). Both media were 
pre-warmed to 37 °C. PHH culture medium was removed 
and replaced with OXPHOS or glycolytic stress test 
medium. Cells were incubated in a CO2-free incubator at 
37 °C for 1 h. 1 µM oligomycin, 0.25 µM FCCP and 1 µM 
rotenone–antimycin-A (OXPHOS stress test) and 25 mM 
glucose, 1 µM oligomycin, and 100 mM 2-deoxyglucose 
solutions (glycolytic stress test) were prepared. Prior to the 
rate measurements, the XFe96 Instrument (Seahorse bio-
sciences, North Billerica, MA) allowed the oxygen partial 
pressure to reach equilibrium. The oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR) 
were measured simultaneously three times to establish a 
baseline rate. After each compound injection, conditions 
were allowed to return to normal oxygen tension and pH. 
The OCR and ECAR measurements for each well were 
recorded and reported as pmol/min and mpH/min, respec-
tively, by XF Wave software. Results were displayed as a 
percentage of maximal OCR and ECAR or as relative fold 
change of each parameter between time points.
Rotenone assay
PHH was plated at 1 × 105 in 96-well collagen-I-coated 
plates. At 24 and 168 h, serial concentrations (0–20 mM) 
of rotenone (Sigma-Aldrich, St. Louis, MO) were made 
in DMSO (Fisher Scientific). Then, the compound solu-
tions were added to culture media at 1/200 (v/v) ratio to 
make final dosing concentrations of 0–100 µM (0.5 % v/v 
DMSO). Culture media were removed and replaced with 
the media containing rotenone. Following incubation for 
2 h (37 °C, 5 % CO2), ATP content was assessed using the 
CellTitre-Glo assay (Promega, Madison, WI), according to 
the manufacturers’ instructions. Briefly, 30 µl of ATP rea-
gent was added to each well containing 100 µl of media. 
The plate was shaken (1 min), and then, 100 µl of the well 
content was transferred to a white 96-well plate, and the 
ATPase luminescence was measured using a plate reader 
(Varioskan, Thermo Scientific, Waltham, MA). Results 
were presented as percentage of control.
Results
Global proteomics reveals donor‑dependent variation 
as a major influence on dedifferentiation
iTRAQ quantitative global proteomic analysis was used to 
assess the changes which occur in PHH at different time 
points during a 168-h monolayer culture. Dedifferentiation 
and loss of characteristic hepatocyte morphology were con-
firmed by microscopy. Figure 1a shows images of the cells 
taken at 24, 72 and 168 h and clearly demonstrates the main-
tenance of confluency and the loss of the typical hepatocyte 
polygonal morphology (24 h), towards a culture with flatter 
and less defined epithelial characteristics at 72 and 168 h.
A total of 3430 unique proteins were detected across 
three iTRAQ runs (table S1), with 1117 identified across all 
samples. Statistical analysis using a linear model yielded 
significantly differentially expressed proteins (DEPs) at 
each time point relative to freshly isolated cells (table S2). 
These changes highlight a dynamic and escalating process; 
40 DEPs are seen after 24 h, 118 after 72 h and 272 after 
168 h in culture (p < 0.05). When displayed as volcano 
plots (log fold change vs. p value), the increasing disper-
sion and direction of change of the proteins over time in 
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Fig. 1  Morphological and statistical analysis a morphological 
changes in primary human hepatocytes over 168 h in monolayer col-
lagen-I-coated plate culture. Scale bar represents 10 µm; b volcano 
plot analysis of the iTRAQ detected proteins log fold change ver-
sus p value at 24, 72 and 168 h. Blue significantly altered proteins 
(n = 5; p ≤ 0.05) and red significantly altered after multiple testing 
correction (n = 5; Benjamini–Hochberg ≤0.05) c hierarchal cluster-
ing analysis showing the relationship between donors and time points 
(n = 5); d heatmap of each donor’s proteome during dedifferentiation 
relative to the freshly isolated sample. Red indicates down-regulation, 
yellow up-regulation. The intensity of colour reflects the degree of 
change
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culture are strikingly evident (Fig. 1b); interestingly, at 
both 24 and 72 h of culture, the majority of DEPs increased 
in expression.
Hierarchical clustering of the entire dataset shows that 
the dominant factor in determining how the samples are 
related is in fact the original source of the cells, rather than 
time in culture (Fig. 1c). This is particularly pronounced 
at the 24 and 72 h time points, which cluster according to 
donor in every case. The separation from the other donors 
is still evident at 168 h for donors 2 and 5, although these 
samples do cluster away from the earlier time points, 
whereas by this time the other three donors (1, 3 and 4) 
cluster together, demonstrating a convergence towards a 
dedifferentiated phenotype which is more reflective of time 
in culture than the cell source. Thus, these data suggest 
that phenotypic characteristics of the donor have a greater 
impact on the protein dedifferentiating expression profile 
of the hepatocytes than does the length of time in culture, 
particularly over the first 72 h of culture. The variability 
between donor proteomic profiles during dedifferentiation 
is further shown by the heatmap in Fig. 1d.
To identify the proteins with the greatest variability 
across the 5 donors at the different time points, coeffi-
cient of variance (CV) analysis was then used (table S3). 
This criterion highlights a number of proteins, including 
CYP2C9, which is known to vary in expression between 
individuals (Sistonen et al. 2009), and glutamine syn-
thetase, which is associated with differential expression 
according to liver zonation (Jungermann and Kietzmann 
1996). In fact, zonation appears to be a large influencing 
factor on variation during culture as our pathway analysis 
of the most variable proteins revealed significant associa-
tion with ketogenesis, cholesterol biosynthesis, fatty acid β 
oxidation and glutamine synthesis (table S4), all of these 
are related to the portocentral axis gradient of the lobule 
(Godoy et al. 2013).
The most stable proteins during dedifferentiation were 
also investigated (Table S5). These included several mito-
chondrial proteins within the ten most stable proteins. 
Thus, while many proteins show conserved differential 
expression or high levels of inter-donor variability, a sub-
set of proteins remains relatively stable and consequently 
may retain in vivo-like functionality and also serve as use-
ful normalisers for protein expression changes.
Table S6 highlights the most up- and down-regulated 
DEPs at each time point, as assessed by log2 fold change 
relative to the fresh sample. Interestingly, the first noticea-
ble effects at 24 h are an increase in stress-related mediator 
superoxide dismutase and a decrease in histone proteins. 
Of note, hepatic-associated proteins are not universally 
down-regulated, as exemplified by alpha-1-antitrypsin and 
cytokeratins 8 and 18, which are up-regulated throughout 
the analysis (Table S2 and S6). Interestingly, these proteins 
are readily detectable in hepatocyte-like cells derived from 
stem cells (Rambhatla et al. 2003), whereas many of the 
down-regulated proteins are not, demonstrating that sim-
ple in vitro culture systems may support similar expres-
sion patterns during both hepatic dedifferentiation and 
differentiation.
Pathway analysis reveals the key changes and dynamic 
profile of dedifferentiation
Pathway enrichment analysis was used to identify the 
affected functions and pathways which underlie dedifferen-
tiation. A list of the most significantly perturbed pathways 
and functions at the three time points is shown in table S7.
Heatmap analysis of the biological functions at the three 
post-isolation time points (Fig. 2a) shows the differential 
dynamics of the pathway groups. Many of the pathways 
follow a linear pattern of increasing activation or inhibition; 
however, some, such as the cell survival pathways, display 
different dynamics, as they are predicted to be activated at 
72 h, but not at 24 or 168 h. Figure 2b displays the canoni-
cal pathways at the assessed time points. Whilst metabolic 
pathways display a trend of increasing significance during 
culture, acute phase response signalling and ROS/NOS pro-
duction are significantly affected at 24 h, but not at 168 h. 
Taken together, these data indicate a time point-dependent 
cellular response to isolation and culture (figure S1).
Upstream regulation analysis (i.e. transcription factors, 
cytokines, growth factors and receptors) was then used 
to predict which regulators were activated or inhibited 
(Fig. 2c). The results suggest an activation of proliferative 
and inflammatory regulators and inhibition of metabolic-
associated factors. Moreover, many energy production-
associated factors are down-regulated at 168 h including 
PPARα, insulin receptor, KLF15 and the mitochondrial 
transcription factor TFAM.
Analysis of mitochondrial functional profile reveals 
donor variation in the bioenergetic profile
Pathway analysis predicted a perturbation of energy pro-
duction and mitochondrial mechanics; therefore, we inves-
tigated the mitochondrial proteome in further detail. The 
Fig. 2  Pathway analysis of dedifferentiation a biological functions 
associated with the DEPs according to Z-activation score. If score 
2 ≥ Z-score ≤ −2, the function is predicted to be activated or inhib-
ited, respectively. Red up-regulated, green down-regulated. Inten-
sity of colour correlates with greater Z-activation score b canonical 
pathways during dedifferentiation. Results displayed—Log (p val-
ues), pathway included if p < 0.05 at any of the assessed time points. 
Colour Intensity corresponds to the significance value; c upstream 
regulators predicted to be either activated or inhibited by Z-activation 
score (2 ≥ Z-score ≤ −2). Red activated, green inhibited, in order of 
significance
▸
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expression of proteins with known mitochondrial asso-
ciations demonstrated a general downward trend of the 
DEPs (bold) with time in culture, particularly at 168 h, 
with superoxide dismutase II being a notable exception 
(Fig. 3a). However, a number of key mitochondrial pro-
teins, such as mitochondrial import receptor subunits, 
remained largely unchanged (table S5). This indicates that 
the large-scale down-regulation of mitochondrial proteins 
represents an alteration in function between freshly isolated 
cells and 168 h rather than a generalised loss of mitochon-
drial mass between these time points.
Pathway analysis was then used to assess the mitochon-
drial proteomic dataset DEPs. This analysis revealed pre-
dicted roles for AMPK signalling, a master regulator of 
energy metabolism, which increases in significance during 
time in culture (Figure S2a). Furthermore, a negative regu-
lator of mitochondrial fusion, OMA-1, is also predicted to 
be down-regulated (figure S2b).
To assess how these changes impacted mitochondrial 
function, oxygen consumption rate (OCR) and extracel-
lular acidification rate (ECAR) at 24 and 168 h were sub-
sequently investigated in PHH isolated from a further five 
donors. The analysis demonstrated a clear variation in indi-
vidual bioenergetic OCR profiles at 24 h (Fig. 3b (i)), with 
the 168-h profile showing greater dependence on the 24 h 
profile, rather than time in culture. Analysis of glycolytic 
consumption, as measured by ECAR, shows much greater 
donor-dependent variation (Fig. 3b (ii)), which may be 
attributable to the known gradient of glycolysis across the 
portocentral axis, and is consistent with our findings regard-
ing the most variable proteins. Despite this variation, a trend 
emerges: basal glycolysis shows an increase during culture 
in donors with lower basal glycolysis, whereas those with 
higher basal levels at 24 h decrease, suggestive of a conver-
gence towards a culture-dependent level of basal glycolysis.
Furthermore, many of the tested OCR parameters 
remain remarkably stable between 24 and 168 h (Fig. 3b 
(iii)), despite the large-scale changes to the mitochondrial 
proteome. ECAR measurements showed similar stability; 
however, there was a general trend of increased glycolytic 
parameters, including the only significantly altered factor, 
namely glycolytic reserve (Fig. 3b (iv)).
Further investigation of the proteomic data revealed a 
significant down-regulation of three complex I subunits, 
whereas the remaining nine detected subunits were not 
significantly differentially expressed. To assess the func-
tional consequence of these changes, rotenone was used 
as a model of complex I mitochondrial perturbation. A 
significant increase in PHH resistance to rotenone toxicity 
in all donors at 168 h regardless of background bioener-
getic (OCR/ECAR) profile (Fig. 3c) was found. Together 
these data suggest that, despite the variability seen between 
donors, a conserved change in essential mitochondrial 
function is observed as a result of time in culture.
Assessment of ADME proteins during dedifferentiation 
reveals selective protein down‑regulation
A well-known feature of hepatocyte dedifferentiation is the 
loss of the metabolic phenotype. To distinguish whether 
this is a selective or global loss of metabolic competence, 
several protein subsets generated in this analysis were com-
pared: 168 h DEPs, 168 h non-DEPs, most stable proteins 
and the most variable proteins. PANTHER analysis was 
used to compare the associated biological function catego-
ries of each subset (Figure S3). This analysis revealed simi-
lar percentages of proteins in each class, with the greatest 
proportion of proteins associated with metabolism in all 
subsets, indicating a selective, rather than wholesale altera-
tion, in the hepatocyte metabolic profile.
Figure 4a shows the known phase I, II and III drug-
metabolising enzymes (Guo et al. 2011), which were 
detected by proteomic analysis. The heatmap highlights the 
loss of metabolic competence with the majority of phase 
I enzymes following a relatively linear pattern of down-
regulation towards 168 h. Phase II/III enzymes appear to 
show greater stability with some phase III proteins, includ-
ing multidrug resistance protein 1 (MDR1) and major vault 
protein (MVP), demonstrating an up-regulation during 
culture.
Figure 4b demonstrates the dedifferentiation pattern of 
the cytochrome P450 s detected by iTRAQ over the 168-h 
period. The general trend of expression relative to freshly 
isolated PHHs is downward; however, the majority of the 
detected CYP proteins are maintained in expression at 
24 h in relation to the freshly isolated cells, showing that at 
24 h the metabolic potential of PHH is mostly maintained 
(Fig. 4b and table S8). Some CYPs displayed greater sta-
bility, such as 2C18 and 4F11, whilst 2B6 and 2C9 dem-
onstrated downward trends, but showed greater variation 
between the donors.
Western blotting for CYP proteins 2D6, 2E1 and 1A2 
was consistent with the iTRAQ results, further demonstrat-
ing a downward trend with noted variation in the individual 
Fig. 3  Mitochondrial changes during dedifferentiation. a Log2 fold 
change of mitochondrial proteins. Red up-regulated, green down-reg-
ulated. Intensity of colour log2 fold change. Bold proteins differen-
tially expressed at 168 h (p < 0.05); b (i) oxidative phosphorylation 
and (ii) glycolysis parameters as percentages of maximal oxygen con-
sumption rates and extracellular acidification rate, respectively; rela-
tive fold change of (iii) oxidative phosphorylation and (iv) glycolysis 
parameters. (*) p < 0.05 two-tailed paired t test; c ATP levels at 24 
(filled diamond) and 168 h (filled square) following rotenone treat-
ment. Results: percentage of control, (*) p < 0.05 two-tailed paired t 
test and (†) p < 0.05 Wilcoxon signed rank test (n = 5)
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dedifferentiation profiles (Fig. 4c). Conversely, β-actin was 
up-regulated during the culture period, which was in keep-
ing with the majority of cytoskeletal proteins detected by 
iTRAQ proteomics (n.b. iTRAQ relative quantification of 
β-actin is not included in table S2 as it did not meet the 
stringent criteria used for the analysis) and the pathway 
analysis (Fig. 2a). Furthermore, analysis of CYP450 activ-
ity using probe substrates for CYP3A and 2D6 shows a loss 
of functional capacity that is mostly consistent with the loss 
of protein recorded by iTRAQ and western immunoblotting 
(Fig. 4d). Interestingly, despite the increase in CYP3A4 
protein at 168 h, no corresponding increase in CYP3A 
activity was detected; these results are in keeping with pre-
vious work which has shown that CYP protein expression 
does not correlate with activity in all situations (Rodriguez-
Antona et al. 2002) and may represent the presence of the 
CYP3A4 protein in a non-functional state.
In contrast to the CYPs, the protein expression of the 
transporters identified as being important for drug influx 
and efflux in the liver (Zamek-Gliszczynski et al. 2012) is 
relatively stable throughout the 168-h culture. Only 2 of 
the 9 detected transporters are significantly down-regulated 
at 168 h (p < 0.05; Fig. 4e); interestingly, these are both 
influx transporters (SLCO1B1 and SLCO1B3). The general 
trend of the other detected drug influx transporters is also 
downwards, as are the trends for efflux transporters MRP6 
and BSEP. Conversely, the remaining efflux transporters 
(MDR1, MRP2 and MRP3) show a maintenance or upward 
trend in expression during culture.
Comparison of the trend in the CYP and transporter pro-
teins with previously published hepatocyte monolayer gene 
expression data (Richert et al. 2006) allows further investiga-
tion of the loss of metabolic competence (table S8). All CYPs 
with a reported gene expression >30 % at 72 h maintained 
protein expression >60 % at 168 h. Conversely, at 72 h, the 
mRNA of CYP1A2, 2A6, 2B6, 2C8, 2E1, 3A4, 4A11, 4F2, 
4F3 and 27A1 is reported to drop to below 10 % of freshly 
isolated PHH (Richert et al. 2006). When the protein expres-
sion of these CYPs is compared, the majority, with the excep-
tion of CYP4F2 and 4F3, show significant down-regulation at 
168 h, suggesting that the loss of CYPs can be mainly asso-
ciated with reduced transcription. This association is shown 
in figure S4, demonstrating a good correlation between 
mRNA at 72 h and protein at 168 h in the down-regulated 
CYPs. Some phase III proteins appear to show greater stabil-
ity, including BSEP, SLC22A7 and SLC22A1 which have 
mRNA <10 % at 72 h; however, despite a downward trend, 
they are not significantly down-regulated at 168 h.
Pathway analysis of ADME proteins reveals the 
pathways and transcription factors predicted 
to underlie the loss of specific metabolic functions
Targeted analysis of the transcription factors that are asso-
ciated with the ADME DEPs revealed the specific regula-
tors, which are significantly perturbed and may cause the 
loss of ADME proteins during dedifferentiation (table S9). 
In keeping with published literature (Fraczek et al. 2013), 
HNF1α, C/EBP and HNF1β were amongst the most sig-
nificantly associated regulators with the loss of metabolic 
competence. Interestingly, FECH (ferrochelatase), a key 
enzyme in the production of heme, found to be signifi-
cantly down-regulated at 168 h (table S2), is highly asso-
ciated with the differentially expressed ADME proteins. 
SMARCB1 is also significantly associated with the ADME 
proteomic profile at 168 h.
Investigation into the predicted transcription factor bind-
ing sites of differentially expressed and non-differentially 
expressed CYPs revealed the factors that may underlie the 
selectivity found in the loss of xenobiotic CYPs (Table 
S10). This analysis predicted binding sites for HSF2 to be 
highly enriched in the CYPs which were not differentially 
expressed, whereas ZEB1, FOXO1 and NF-Y binding sites 
are almost exclusively predicted to be located upstream of 
the differentially expressed CYPs.
Discussion
In this study, we have demonstrated the first use of global 
proteomics as a tool for investigating primary human 
hepatocyte dedifferentiation, identifying new targets and 
generating new hypotheses for future examination in sim-
ple and complex culture models.
Throughout the analysis, differentially expressed pro-
teins and associated pathways were found at every time 
point, suggesting that these mechanisms are well conserved 
across donors. The number of significantly differentially 
expressed proteins increased at each time, which, together 
with the clustering analysis, suggests an increasing devia-
tion from the freshly isolated donor phenotype. Grouping 
of these data showed that dedifferentiation is not solely a 
change in expression of whole protein classes, but that it is 
a complex, differentially controlled and active process, in 
which selected pathways and functions from many classes 
are up- or down-regulated.
Fig. 4  Loss of hepatic metabolic phenotype. a ADME phases I, II 
and III enzyme heatmap. Red up-regulated, green down-regulated. 
Intensity of colour relative fold change. Data derived from n ≥ 3 
donors unless stated (†) n = 2 or (‡) n = 1; b CYP450 s over 168 h 
(n = 5); error bars SD; one-way ANOVA: (*) p < 0.05, (#) p < 0.01); 
c western blots for CYP450 s and β-actin; d metabolic function of 
CYP3A (testosterone) and CYP2D6 (dextromethorphan) and detec-
tion of respective metabolites (6β-OH-testosterone and dextrorphan) 
detected by LC–MS–MS (n = 3; error bars SD); e ADME transport-
ers protein expression during dedifferentiation. Error bars SD,* sig-
nificant p < 0.05 by one-way ANOVA
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Cytochrome P450s has been strongly associated with 
a loss of expression during culture (Rodriguez-Antona 
et al. 2002), and this is further demonstrated here by the 
top three most down-regulated proteins at 168 h: CYP2A6, 
CYP2C8 and CYP4A11. However, this study allows for 
these changes to be put into the context of the global cell 
proteome, revealing the strikingly selective nature of dedif-
ferentiation. Even within single P450 families, selectivity 
can be seen. For example, whilst CYP2A6 and CYP2C8 are 
the most down-regulated proteins, CYP2C18 and CYP2J2 
remain unaltered by culture conditions. Of further interest, 
CYP2A6 has been reported to be the largest discriminant 
between foetal and adult hepatocytes (Rowe et al. 2013); 
here, we show CYP2A6 to be the largest discriminator 
between freshly isolated and 168 h cultured hepatocytes.
Understanding how this specificity works is a key ques-
tion in determining new strategies for hepatocyte culture 
and for stem cell differentiation protocols. By comparing 
predicted transcription factor binding, we have been able to 
generate a list of enriched transcription factors associated 
with either differentially expressed or non-differentially 
expressed CYPs. Future investigations to elucidate the 
roles of these factors (e.g. HSF2, SP1 and ZEB1) may lead 
to a greater understanding of the selective loss/maintenance 
of metabolic competence during dedifferentiation. For 
example, ZEB1, a key mediator of epithelial–mesenchymal 
transition (EMT), may in part explain the link between the 
maintenance of epithelial phenotype and CYP expression.
Comparisons between differentially expressed and 
non-differentially expressed drug-metabolising proteins 
revealed no single factor which could mediate all the 
ADME-associated proteomic changes. The results corrob-
orate previous reports showing the importance of HNF1α 
alongside HNF1β, C/EBP and FOXA1 in dedifferentia-
tion (Padgham et al. 1993). Despite being a well-accepted 
major determinant of hepatic function (Odom et al. 2004), 
the lack of association of HNF4α with differentially 
expressed ADME proteins is consistent with HNF4α over-
expression studies in rat hepatocytes, which failed to re-
establish xenobiotic metabolic function (Naiki et al. 2005). 
The association of the enzyme ferrochelatase is also of 
interest. Ferrochelatase catalyses the final step of the heme 
production pathway, and thus, its loss of expression would 
likely reduce the intracellular heme concentration. CYPs 
are dependent on heme for function, and its loss during 
culture has been reported in mouse hepatocytes (Singh and 
Veltri 1991). HNF1α has been shown to regulate ferroche-
latase expression (Muppala et al. 2000) and may provide an 
additional indirect mechanism by which HNF1α can alter 
ADME protein expression.
One potential cause of the change in the hepato-
cyte ADME and proteome-wide phenotype is through 
alterations in the accessibility of DNA to transcriptional 
machinery. Our results strongly predict a down-regulation 
of SMARCB1, a member of the BAF complex, which is 
thought to remodel chromatin structure (Wilson and Rob-
erts 2011). SMARCB1 been shown to be essential for 
hepatocyte differentiation (Gresh et al. 2005), and recent 
work has also linked another member of the BAF com-
plex, SMARCA4, to the enhancement of the hESC-derived 
HLC phenotype (Mobus et al. 2015). Alterations in chro-
matin accessibility and transcription factor binding are one 
of the key first steps in the reprogramming of somatic cells 
to induced pluripotent stem cells (Papp and Plath 2013), 
and similar fundamental mechanisms may play a role in 
the acquisition of the dedifferentiated phenotype. Efforts 
to intervene epigenetically using histone deacetylase and 
DNA methyltransferase inhibitors have been successful in 
maintaining expression of hepatic functions, although the 
exact mechanisms are unclear (Fraczek et al. 2012, 2013). 
Taken together, these results highlight the importance of 
epigenetic regulation in the dedifferentiation process; how-
ever, the consequences of these changes and the mecha-
nisms which underlie them remain unclear and require fur-
ther investigation.
Energy production is another fundamental cellular pro-
cess affected by dedifferentiation that is highlighted by 
this study. The proteomic and functional data suggest a 
dramatic remodelling of the bioenergetic proteome dur-
ing monolayer culture. These changes lead to a reduction 
in many mitochondrial-associated proteins, particularly 
those involved in lipid and fatty acid metabolism. Previ-
ous work has implicated AMPK signalling and mitochon-
drial fusion as part of the adaptation and repolarisation of 
hepatocytes in sandwich culture following isolation (Fu 
et al. 2013). Here we have additionally shown both AMPK 
and mitochondrial fusion pathways to be associated with 
the bioenergetic adaption to a monolayer culture system. 
Furthermore, given the remarkable stability of oxidative 
phosphorylation following plating, during a period of sub-
stantial phenotypic change, it appears that these essential 
processes are preferentially maintained, potentially at the 
expense of non-survival-essential proteins/functions. One 
possible driving factor of these findings is the MEK/ERK 
pathway, which is highlighted by this and other studies 
(Zellmer et al. 2010), as a factor in dedifferentiation and 
has previously been shown to reduce rotenone toxicity 
in neuronal cells (Jiang et al. 2006) and alter both mito-
chondrial function (Ripple et al. 2013) and lipid/fatty acid 
metabolism (Yousefi et al. 2012).
Our analysis revealed that the early stages of dedifferen-
tiation are predominantly donor-dependent with the inter-
individual variation that exists in the starting donor pheno-
type being maintained throughout the first 72 h of culture. 
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Hepatocytes are known to vary between donors (due to 
both genotypic and environmental factors) (Bhogal et al. 
2011) and in function depending on their location/zone 
in the lobule portocentral axis (Allen et al. 2005); both of 
these factors also appear to influence the dedifferentiation 
profile during culture. Similarity to the isolated donor phe-
notype dissipates with time in culture in all cases, a conver-
gence towards a reproducible dedifferentiated phenotype 
was observed. Taken together, these data suggest that the 
strictly defined culture system promotes a specific protein 
expression profile, and, as a consequence of the variable 
PHH phenotype at isolation, the proteome changes required 
to achieve this dedifferentiated phenotype are also variable. 
This information has profound implications for the use 
of hepatocytes for early drug discovery and prediction of 
DILI; the majority of toxicological endpoints are assessed 
within 72 h of isolation; thus, the variable dedifferentia-
tion of hepatocytes demonstrated in this study is likely to 
have an impact on attempts to achieve consistent biological 
assessment of multiple chemical variables (e.g. libraries of 
new drugs).
Many of the earliest changes in protein expression dur-
ing dedifferentiation are related to cell survival and the 
maintenance of homoeostatic functions. The up-regulation 
of stress-induced survival pathways may be considered as a 
double-edged sword, on the one hand preventing apoptosis/
necrosis and allowing cells to survive during culture, whilst 
on the other, playing an important role in the loss of the 
hepatic phenotype. Negative regulation of the hepatic phe-
notype has been reported to be true for the MEK/ERK and 
NFκB pathways (Elaut et al. 2006; Fraczek et al. 2013) and 
is predicted to be up-regulated by this study. Additionally, 
the most significantly predicted up-regulated factor at 168 h 
was heat shock factor 2 (HSF2). Overexpression studies 
have shown HSF2 to inhibit erythroid differentiation, but 
to our knowledge, HSF2 has not previously been linked to 
the hepatic differentiation status (Leppä et al. 1997). Such 
results emphasise the apparent trade-off between cell sur-
vival and a mature hepatic phenotype in traditional in vitro 
systems. Therefore, reducing cellular stress at all stages of 
culture, particularly during isolation, may be the most suc-
cessful method of maintaining both cell viability and the 
hepatic phenotype.
Whilst some of the results yielded in this study may be 
specific to monolayer culture, the use of a rudimentary cul-
ture system has allowed the identification of a wide array 
of known and novel mechanisms through which dediffer-
entiation influences hepatic phenotype. We believe this 
approach enables a holistic understanding of the hepatocyte 
dedifferentiation process, and the knowledge gained in this 
study has the potential to enhance complex culture systems 
towards an improved physiological phenotype.
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